Assay development and screening for discovery of chemical probes, drugs or immunomodulators (R01 Clinical Trial Not Allowed)
Grant Opportunity Analysis
The National Institutes of Health (NIH) is offering a funding opportunity titled "Assay Development and Screening for Discovery of Chemical Probes, Drugs or Immunomodulators" through the National Cancer Institute (NCI). This initiative aims to support research focused on the identification and development of small molecules that can elucidate cancer biology and contribute to therapeutic advancements. The funding is intended for various eligible applicants, including educational institutions and non-profit organizations, with a flexible budget and a project duration of up to three years. Key deadlines include an application submission window starting January 5, 2025, and a closing date of September 7, 2026. For further details, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-25-153.html.
Eligible Applicants
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.